5 questions facing biotech M&A in 2022

In 2021, biopharma M&A dipped to one of its lowest levels on record, according to a report released this week by financial services provider EY. At $108 billion, the total value of these deals was only about 40% of what was seen in 2019. EY also estimates that, when looking at all the cash, debt and equity they could use to fund transactions, biopharma buyers deployed just 9% of the nearly $1.2 trillion at their disposal last year.